Phio Pharmaceuticals To Present Data On INSTAYL Compound PH-894 At ASGCT's 2024 Cancer Conference; PH-894 Shows Potent Silencing Of BRD4 In NK Cells, Enhances NK Cell Proliferation And Cytotoxicity
Portfolio Pulse from Benzinga Newsdesk
Phio Pharmaceuticals is set to present data on its INSTAYL compound PH-894 at the ASGCT's 2024 Cancer Conference. The compound shows potent silencing of BRD4 in NK cells, enhancing their proliferation and cytotoxicity.
October 16, 2024 | 12:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Phio Pharmaceuticals will present data on PH-894, which shows potential in enhancing NK cell functions by silencing BRD4. This could be a significant development in cancer treatment.
The presentation of PH-894 data at a major cancer conference highlights its potential in cancer treatment, likely boosting investor interest and positively impacting PHIO's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100